TESARO price target lowered to $43 from $57 at RW Baird Baird lowered its price target on TESARO citing the potential for a significant new competitor for one of its key drugs. The firm believes its Rolapitant P3 commercial thesis remains intact but worry the its competitor's formulation may be closer to reality than previously thought. Shares remain Outperform rated but cautious.
TESARO price target raised to $50 from $44 at Mizuho Mizuho raised its price target for TESARO shares to $50 citing increased confidence and market opportunity for niraparib following the company's Q4 results. The firm expects approval for rolapitant in Q3 and reiterates a Buy rating on the stock.